Abstract

Novel research over the past 2 years has necessitated an update of our 'ABCDE' approach to the metabolic syndrome. Clinical trials investigating the role of aspirin in primary prevention have led to an adjustment in the indication for aspirin in metabolic syndrome patients at intermediate risk of a cardiovascular event. There has been renewed enthusiasm for the use of niacin as second-line treatment for atherogenic dyslipidemia, with fibrates reserved for those with severe residual dyslipidemia. In light of the noteworthy findings of the Justification for the Use of statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin trial, the 'C' category representing 'cholesterol' has been expanded to include the use of high-sensitivity C-reactive protein for guiding statin use and perhaps monitoring statin therapy. Recent evidence confirms that diet and exercise continue to be the cornerstone of any metabolic syndrome treatment strategy. The revised 'ABCDE' approach incorporates the most recent influential studies into a simple yet thorough algorithm for management of the metabolic syndrome.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.